News Related to Resectable Desmoplastic Melanoma

Related coverage linked through entity extraction aliases.

Neoadjuvant Pembrolizumab Achieves 71% pCR in Resectable Desmoplastic Melanoma

Mar 01, 2026

Phase 2 SWOG S1512 trial shows neoadjuvant pembrolizumab achieved 71% pathologic complete response in resectable desmoplastic melanoma with 3-year survival rates of 74% for relapse-free and 87% for overall survival.

Neoadjuvant Immunotherapy Shows High Response Rates in Desmoplastic Melanoma

Feb 27, 2026

Neoadjuvant pembrolizumab achieved 71% pathologic complete response in desmoplastic melanoma patients, while lower-dose ipilimumab combination therapy showed improved survival and fewer side effects in advanced melanoma treatment.